Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers

Autor: S Trebeschi, SG Drago, NJ Birkbak, I Kurilova, AM Cǎlin, A Delli Pizzi, F Lalezari, DMJ Lambregts, MW Rohaan, C Parmar, EA Rozeman, KJ Hartemink, C Swanton, JBAG Haanen, CU Blank, EF Smit, RGH Beets-Tan, HJWL Aerts

INTRODUCTION: Immunotherapy is regarded one of the major breakthroughs in cancer treatment. Despite its success, only a subset of patients responds - urging the quest for predictive biomarkers. We hypothesize that Artificial Intelligence (AI) algorit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::edace40fc60729c94d50df10fede3ad0

Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.

Autor: Martín-Lluesma S; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona; Departamento de Ciencias Médicas Básicas, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain., Svane IM; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark., Dafni U; Faculty of Nursing, National and Kapodistrian University of Athens, Athens, Greece; Department of Oncology, CHUV, University of Lausanne, Lausanne, Switzerland. Electronic address: udafni@nurs.uoa.gr., Vervita K; Scientific Research Consulting Hellas, Statistics Center, Athens., Karlis D; Department of Statistics, Athens University of Economics and Business, Athens, Greece., Dimopoulou G; Scientific Research Consulting Hellas, Statistics Center, Athens., Tsourti Z; Scientific Research Consulting Hellas, Statistics Center, Athens., Rohaan MW; Division of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam., Haanen JBAG; Division of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam; Department of Medical Oncology, Leiden University Medical Oncology, Leiden, Netherlands; Melanoma Clinic, CHUV, Lausanne., Coukos G; Department of Oncology, Lausanne University Hospital and University of Lausanne Ludwig Institute for Cancer Research Lausanne Branch, Switzerland.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Oct; Vol. 35 (10), pp. 860-872. Date of Electronic Publication: 2024 Jul 23.

Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned.

Autor: Borgers JSW; Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam., van Schijndel AW; Department of Intensive Care, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; Department of Cardiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam., van Thienen JV; Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam., Klobuch S; Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam., Seijkens TTP; Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; Department of Medical Biochemistry, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Tobin RP; Department of Surgery, Division of Surgical Oncology, University of Colorado Anschutz Medical Campus, Aurora, USA., van Heerebeek L; Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam., Driessen-Waaijer A; Department of Radiology, Onze Lieve Vrouwe Gasthuis, Amsterdam., Rohaan MW; Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; Department of Radiotherapy, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam., Haanen JBAG; Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands; Melanoma Clinic, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Electronic address: j.haanen@nki.nl.

Publikováno v: ESMO open [ESMO Open] 2024 Feb; Vol. 9 (2), pp. 102383. Date of Electronic Publication: 2024 Feb 15.

"One more chance to survive": the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future care.

Autor: Egeler MD; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. m.egeler@nki.nl., Boomstra E; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Rohaan MW; Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Van den Heuvel NMJ; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Fraterman I; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Delfos M; Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van de Poll-Franse LV; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.; Department of Medical and Clinical Psychology, Center of Research on Psychology in Somatic Diseases (CoRPS), Tilburg University, Tilburg, The Netherlands., Borch TH; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Svane IM; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Haanen JBAG; Division of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Retèl VP; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands., Boekhout AH; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Publikováno v: Journal of cancer survivorship : research and practice [J Cancer Surviv] 2023 Aug 22. Date of Electronic Publication: 2023 Aug 22.

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

Autor: Rohaan MW; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Borch TH; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., van den Berg JH; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Met Ö; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Kessels R; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Geukes Foppen MH; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Stoltenborg Granhøj J; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Nuijen B; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Nijenhuis C; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Jedema I; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., van Zon M; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Scheij S; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Beijnen JH; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Hansen M; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Voermans C; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Noringriis IM; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Monberg TJ; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Holmstroem RB; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Wever LDV; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., van Dijk M; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Grijpink-Ongering LG; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Valkenet LHM; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Torres Acosta A; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Karger M; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Borgers JSW; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Ten Ham RMT; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Retèl VP; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., van Harten WH; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Lalezari F; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., van Tinteren H; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., van der Veldt AAM; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Hospers GAP; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Stevense-den Boer MAM; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Suijkerbuijk KPM; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Aarts MJB; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Piersma D; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., van den Eertwegh AJM; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., de Groot JB; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Vreugdenhil G; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Kapiteijn E; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Boers-Sonderen MJ; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Fiets WE; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., van den Berkmortel FWPJ; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Ellebaek E; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Hölmich LR; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., van Akkooi ACJ; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., van Houdt WJ; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Wouters MWJM; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., van Thienen JV; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Blank CU; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Meerveld-Eggink A; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Klobuch S; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Wilgenhof S; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Schumacher TN; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Donia M; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Svane IM; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.)., Haanen JBAG; From the Division of Medical Oncology (M.W.R., M.H.G.F., M.K., J.S.W.B., J.V.T., C.U.B., A.M.-E., S.K., S.W., J.B.A.G.H.), the BioTherapeutics Unit, Hospital Pharmacy (J.H. van den Berg, C.N., M.Z., S.S.), the Divisions of Pharmacy and Pharmacology (B.N., J.H. Beijnen), Molecular Oncology and Immunology (I.J., T.N.S., J.B.A.G.H.), Biometrics (R.K., L.D.V.W., M. van Dijk, L.G.G.-O., L.H.M.V., A.T.A., H.T.), Psychosocial Research and Epidemiology (R.M.T.H., V.P.R., W.H.H.), Radiology (F.L.), and Surgical Oncology (A.C.J.A., W.J.H., M.W.J.M.W.), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (M.H., C.V.), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (A.J.M.E.), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (R.M.T.H.), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (K.P.M.S.), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (H.T.), and Oncode Institute (T.N.S.), Utrecht, the Department of Health Technology and Services Research, University of Twente (V.P.R.), and the Department of Medical Oncology, Medical Spectrum Twente (D.P.), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (A.A.M.V.), the Department of Medical Oncology, University Medical Center Groningen, Groningen (G.A.P.H.), the Department of Medical Oncology, Amphia Hospital, Breda (M.A.M.S.-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht (M.J.B.A.), the Department of Medical Oncology, Isala, Zwolle (J.-W.B.G.), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (G.V.), the Departments of Medical Oncology (E.K.), Biomedical Data Sciences (M.W.J.M.W.), Hematology (T.N.S.), and Clinical Oncology (J.B.A.G.H.), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (M.J.B.-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden (W.E.F.), and the Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (F.W.P.J.B.) - all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (T.H.B., Ö.M., J.S.G., I.M.N., T.J.M., R.B.H., E.E., M. Donia, I.M.S.), and the Department of Plastic Surgery (L.R.H.), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital - all in Sydney (A.C.J.A.).

Publikováno v: The New England journal of medicine [N Engl J Med] 2022 Dec 08; Vol. 387 (23), pp. 2113-2125.